BioSpace News Archive

Satsuma Pharmaceuticals, Inc . today announced completion of subject enrollment in the Company’s ongoing STS101 SUMMIT pivotal Phase 3 efficacy trial, with more than 1,400 subjects randomized. Satsuma expects to announce topline results from the SUMMIT trial in the fourth quarter of 2022.

Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today reported financial results for the second quarter of 2022 and provided recent business updates.

Aprea Therapeutics, Inc. today announced that Oren Gilad Ph.D, President and Chief Executive Officer, will participate in a panel discussion on synthetic lethality at the 2022 Wedbush PacGrow Healthcare Conference on Tuesday, August 9, 2022 at 12:35 p.m. ET.

PDS Biotechnology Corporation today announced that its management will participate in a fireside chat and one-on-one meetings at the BTIG Biotechnology Conference, a hybrid event taking place August 8-9, 2022.

Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today announced data demonstrating durable lowering of low-density lipoprotein (LDL) cholesterol in non-human primates and the selection of VXX-401 to pursue as its anti-PCSK9 vaccine candidate to treat hypercholesterolemia.

Astria Therapeutics, Inc., a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, granted equity awards on August 1, 2022 under Astria’s 2022 Inducement Stock Incentive Plan.

Goldfinch Bio today announced that Anthony Johnson, M.D., President and Chief Executive Officer of Goldfinch Bio, will participate in a panel discussion, Casino Re-nal – Novel Mechanisms in Renal Disorders , at the Wedbush PacGrow Healthcare Virtual Conference on Tuesday, August 9, 2022.

Xenetic Biosciences, Inc. today announced a research and development collaboration to develop Neutrophil Extracellular Traps targeted, adoptive cell therapies for the treatment of cancer.

Vektor Medical today announced the appointment of three key executives.

Evolus, Inc.today reported financial results for the second quarter ended June 30, 2022 and provided a business update.